Eiffel's Nasdaq view improves as ADR completed
01 June, 2004 by Melissa TrudingerEiffel Technologies (ASX:EIF) has established a Level 1 American Depository Receipt (ADR) program in a first step towards a possible international listing for the company.
BresaGen merger still looks likely
01 June, 2004 by Melissa Trudinger and Renate KrelleThe merger of BresaGen's US-based cell therapy division with San Diego stem cell company Cythera looks like it will go ahead, after the two companies executed the merger agreement last week.
Biosignal animal studies show efficacy
31 May, 2004 by Melissa TrudingerBiosignal (ASX:BOS) has confirmed the efficacy of its furanone molecules in preventing bacterial colonisation of contact lenses in animal studies, paving the way for more extensive human studies.
Ambri to evaluate SensiDX in hospitals
31 May, 2004 by Melissa TrudingerAmbri (ASX:ABI) has installed its SensiDX System at the Royal North Shore Hospital in Sydney for evaluation and expects to install a second system at Sydney's St Vincent's Hospital shortly.
New faces at the Bionomics
27 May, 2004 by Graeme O'NeillAdelaide drug-discovery company Bionomics (ASX:BNO, US OTC:BMICY) has appointed Dr Tim Harris, CEO and co-founder of US biotech Structural GenomiX, to its advisory board.
Ventracor pilot trial to continue
27 May, 2004 by Renate KrelleSydney-based Ventracor (ASX:VCR) today announced its pilot trial, testing the safety of its VentrAssist artifical heart device, will continue.
Phosphagenics seeks listing on UK's AIM
26 May, 2004 by Renate KrelleMelbourne-based Phosphagenics (ASX:POH) -– formerly Vital Capital -– has flagged its intention to seek a dual listing on the London Stock Exchange's Alternative Investment Market (AIM).
CSL outsources anti-venom production to PlasVacc
25 May, 2004 by Melissa TrudingerQueensland based veterinary plasma company PlasVacc has signed and agreement to supply CSL with horse plasma for anti-venom applications.
Fed decision backs GSK lawsuit, says Biota
25 May, 2004 by Melissa TrudingerA federal government decision earlier this month to stockpile Roche's Tamiflu, rather than the anti-flu drug Relenza, designed by Melbourne-based Biota (ASX:BTA), is being used by the Australian firm to support its legal claims that GlaxoSmithKline failed to support and promote Relenza.
Cryosite and Peter Mac team up to store stem cells
24 May, 2004 by Melissa TrudingerSydney-based cryogenic storage company Cryosite (ASX: CTE) has entered into an agreement with Melbourne's Peter MacCallum Cancer Centre to provide long term storage of patients' blood stem cells.
Parental approval for BioPharmica spin off, prospectus launched
24 May, 2004 by Melissa TrudingerThe spin-off and listing of BioPharmica was approved at a general meeting of Grandbridge (ASX: GBA) shareholders today by more than 99 per cent of shareholders.
Playing it safe in science can cause lasting harm: academy president
21 May, 2004 by Graeme O'NeillThe President of the Australian Academy of Science, Dr Jim Peacock, has warned that governments could do “irreparable and lasting harm” by seeking to play safe when confronted by controversial technological change.
AustCancer snaps up US vaccine developer
21 May, 2004 by Melissa TrudingerAustralian Cancer Technologies (AustCancer, ASX: ACU) is the latest Australian company to announce an acquisition of a US company, with its proposal to acquire US vaccine developer Galenica Pharmaceuticals for around US$5 million in shares.
The GM ban: what it will mean for plant biotech
20 May, 2004 by Graeme O'NeillThe future of the Victorian wheat industry has moved from a biosecure glasshouse into a small, netted field plot at the International Centre for Cereal Breeding (CIMMYT) in Mexico.
Political science: behind the GM ban
20 May, 2004 by Graeme O'NeillAlmost two months ago, the Victorian Labor government stunned the state's biotechnology industry by imposing a four-year, legislated moratorium on genetically modified (GM) canola cropping.
